Mainz Biomed NV (NASDAQ:QUCY) Short Interest Up 996.3% in May

Mainz Biomed NV (NASDAQ:QUCY) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 10,530,990 shares, a growth of 996.3% from the April 30th total of 960,587 shares. Currently, 79.6% of the shares of the stock are sold short. Based on an average trading volume of 79,673,861 shares, the short-interest ratio is currently 0.1 days.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on QUCY. Maxim Group lowered Mainz Biomed from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. Weiss Ratings raised Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Reduce”.

Mainz Biomed Price Performance

NASDAQ QUCY traded down $0.54 on Wednesday, reaching $2.93. 6,415,368 shares of the company were exchanged, compared to its average volume of 50,886,420. The firm has a fifty day simple moving average of $1.04. The company has a market cap of $42.95 million, a PE ratio of -0.04 and a beta of 0.42. Mainz Biomed has a fifty-two week low of $0.30 and a fifty-two week high of $4.93.

Mainz Biomed (NASDAQ:QUCY) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.02) earnings per share for the quarter. The business had revenue of $0.13 million during the quarter.

About Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.